Home
Sample Assessment Form
Learning Objectives:
Charles Howell, MD (speaker)
"Understand the efficacy of bocoprevir and telaprevir (FDA-approvod HCV NS3 protease
Inhibitors) treatments for chronic HCV genotype 1."
Compare the risks, benefits and side effect profiles of of boceprevir and telaprevir therapy.
Choose best answer: HCV NS3 protease inhibitors, boceprevir and telaprevir:
*
A: "are approved for use as single agents (monotherapy) for HCV treatment"
B: are effective against HCV genotypes 1, 2, 3, 4, 5 and 6
C: have safety profiles that do not differ appreciably from peginterieron alfa-2 and ribavirin
D: must be used in combination with peginterferon alfa-2 and ribevlrin
True or false: Unlike peginterferon and ribavirin treatments for HCV, the sustained virologic response (SVR) achieved with HCV NS3 protease inhibitors does not vary by baseline viral load, HCV 1 subtype, race, and amount of liver fibrosis (scar tissue):
*
A: TRUE
B: FALSE
For patients who failed to achieve a SVR after prior therapy with peginterferon alfa-2 and ribavirin, treatment with either boceprevir or telaprevir:
*
A: Is typically unsuccessful in eradicating HCV genotype 1
B: The likelihood of a SVR depends on the type of treatment failure (relapse, partial response, null response) observed during the previous treatment.
C: Will yield a SVR rate that is comparable to the SVR rate that we would expect if the patient had not been previously treated for HCV
D: Is less likely than the initial therapy to cause severe treatment-related side effects
True or False: Boceprevir and Telaprevir are metabolized by cytochrome P450 3A, but remarkably these medications have little potential for interactions with therapies commonly used in patients with chronic HCV:
*
A: TRUE
B: FALSE
